Can a daily pill bring back hair in severe alopecia?

NCT ID NCT07749716

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an experimental oral medication, VC005, in adults with severe alopecia areata—an autoimmune condition that causes patchy or complete hair loss. Participants will take either VC005 or a placebo daily for 24 weeks. The main goal is to see if the drug can reduce hair loss severity, measured by a standard scoring tool, and to assess its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VC005 tablets
What this could lead to
If successful, VC005 could offer a new oral treatment option for people with severe alopecia areata, potentially restoring significant hair growth.
What could go wrong
This is an early-phase trial with a modest number of participants, so results may not hold up in larger studies. The drug may also have side effects or fail to outperform a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Peking University People's Hospital, Beijing, Beijng

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.